InterPAD - DETAILS

Fludarabine, 21679-14-1, F-Ara-A, 2-Fluoro Ara-A, (2R,3S,4S,5R)-2-(6-Amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 9-beta-D-Arabinofuranosyl-2-fluoroadenine, Fludarabine [INN], Fludarabina, Fludarabinum, Fluradosa, 2-F-ara-A, Fludarabinum [Latin], CCRIS 3382, NSC 118218, 2-Fluoro-9-beta-D-arabinofuranosyladenine, 2-F-ARAA, 2-fluorovidarabine, 9-b-d-arabinofuranosyl-2-fluoroadenine, Fludarabine (INN), (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, DTXSID4039657, UNII-P2K93U8740, HSDB 6964, 2F-Ara-A, NSC 118218H, (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, EINECS 244-525-5, MFCD00132942, NSC-118218, P2K93U8740, 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-, MLS000028687, DTXCID2019657, Adenine, 9-beta-D-arabinofuranosyl-2-fluoro-, 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine, Fludarabinum (Latin), Fludarabine (Fludara), SMR000058874, 2-Fluoroadenine-9-beta-D-arabinofuranoside, 2-Fluoroadenine arabinoside, Fludarabina [Spanish], FaraA, Fluradosa (TN), CAS-21679-14-1, 2-FLUORO-9-ARABINOADENINE, F-ara-A;NSC 118218, NSC118218, NCGC00181336-01, Fludarabine free base, Fludarabine des-phosphate, FLUDARABINE [MI], 2-FLUORO-ARA-A, FLUDARABINE [HSDB], FLUDARABINE [VANDF], SCHEMBL3510, CHEMBL1568, FLUDARABINE [WHO-DD], MLS006011578, cid_657237, GTPL4802, BDBM68391, CHEBI:94701, EX-A833, L01BB05, BCPP000227, GLXC-04596, HMS2232K13, HMS3259F09, HMS3413N14, HMS3677N14, HMS3715F15, BCP01383, HY-B0069, Tox21_112795, Tox21_113419, HG1007, s1491, AKOS015854911, AKOS015916481, Tox21_113419_1, BCP9000693, CCG-221147, DB01073, DS-1271, NC00633, 2-Fluoro-9-beta-arabinofuranosyladenine, 9-ss-D-Arabinofuranosyl-2-fluoroadenine, NCGC00021920-04, NCGC00181336-03, NCGC00182047-03, BP-25389, BP-55389, AM20090199, F0658, NS00003718, EN300-52641, C21550, D07966, AB00383071-11, AB00383071_13, SR-01000000270, 2-FLUORO-9-.BETA.-D-ARABINOFURANOSYLADENINE, 9-.BETA.-D-ARABINOFURANOSYL-2-FLUOROADENINE, 9-|A-D-Arabinofuranosyl-2-fluoro-9H-purin-6-amine, SR-01000000270-2, 9-(?-D-Arabinofuranosyl)-2-fluoro-9H-purin-6-amine, FLUDARABINE PHOSPHATE IMPURITY E [EP IMPURITY], Z756440078, 9-.BETA.-D-ARABINOFURANOSYL-2-FLUORO-9H-PURIN-6-AMINE, FLUDARABINE PHOSPHATE IMPURITY, 2-FLUORO-ARA-ADENINE- [USP IMPURITY], (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol, (2R,3S,4S,5R)-2-(6-amino-2-fluoro-purin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol, (2R,3S,4S,5R)-2-(6-azanyl-2-fluoranyl-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, 2-Fluoroadenine-9-beta-D-arabinofuranoside, DNA synthesis and methylation inhibitor

Name	Fludarabine
PubChem CID	657237
Molecular Weight	285.23g/mol
Synonyms	Fludarabine, 21679-14-1, F-Ara-A, 2-Fluoro Ara-A, (2R,3S,4S,5R)-2-(6-Amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, 9-beta-D-Arabinofuranosyl-2-fluoroadenine, Fludarabine [INN], Fludarabina, Fludarabinum, Fluradosa, 2-F-ara-A, Fludarabinum [Latin], CCRIS 3382, NSC 118218, 2-Fluoro-9-beta-D-arabinofuranosyladenine, 2-F-ARAA, 2-fluorovidarabine, 9-b-d-arabinofuranosyl-2-fluoroadenine, Fludarabine (INN), (2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, DTXSID4039657, UNII-P2K93U8740, HSDB 6964, 2F-Ara-A, NSC 118218H, (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, EINECS 244-525-5, MFCD00132942, NSC-118218, P2K93U8740, 9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro-, MLS000028687, DTXCID2019657, Adenine, 9-beta-D-arabinofuranosyl-2-fluoro-, 9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine, Fludarabinum (Latin), Fludarabine (Fludara), SMR000058874, 2-Fluoroadenine-9-beta-D-arabinofuranoside, 2-Fluoroadenine arabinoside, Fludarabina [Spanish], FaraA, Fluradosa (TN), CAS-21679-14-1, 2-FLUORO-9-ARABINOADENINE, F-ara-A;NSC 118218, NSC118218, NCGC00181336-01, Fludarabine free base, Fludarabine des-phosphate, FLUDARABINE [MI], 2-FLUORO-ARA-A, FLUDARABINE [HSDB], FLUDARABINE [VANDF], SCHEMBL3510, CHEMBL1568, FLUDARABINE [WHO-DD], MLS006011578, cid_657237, GTPL4802, BDBM68391, CHEBI:94701, EX-A833, L01BB05, BCPP000227, GLXC-04596, HMS2232K13, HMS3259F09, HMS3413N14, HMS3677N14, HMS3715F15, BCP01383, HY-B0069, Tox21_112795, Tox21_113419, HG1007, s1491, AKOS015854911, AKOS015916481, Tox21_113419_1, BCP9000693, CCG-221147, DB01073, DS-1271, NC00633, 2-Fluoro-9-beta-arabinofuranosyladenine, 9-ss-D-Arabinofuranosyl-2-fluoroadenine, NCGC00021920-04, NCGC00181336-03, NCGC00182047-03, BP-25389, BP-55389, AM20090199, F0658, NS00003718, EN300-52641, C21550, D07966, AB00383071-11, AB00383071_13, SR-01000000270, 2-FLUORO-9-.BETA.-D-ARABINOFURANOSYLADENINE, 9-.BETA.-D-ARABINOFURANOSYL-2-FLUOROADENINE, 9-\|A-D-Arabinofuranosyl-2-fluoro-9H-purin-6-amine, SR-01000000270-2, 9-(?-D-Arabinofuranosyl)-2-fluoro-9H-purin-6-amine, FLUDARABINE PHOSPHATE IMPURITY E [EP IMPURITY], Z756440078, 9-.BETA.-D-ARABINOFURANOSYL-2-FLUORO-9H-PURIN-6-AMINE, FLUDARABINE PHOSPHATE IMPURITY, 2-FLUORO-ARA-ADENINE- [USP IMPURITY], (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol, (2R,3S,4S,5R)-2-(6-amino-2-fluoro-purin-9-yl)-5-methylol-tetrahydrofuran-3,4-diol, (2R,3S,4S,5R)-2-(6-azanyl-2-fluoranyl-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, 2-Fluoroadenine-9-beta-D-arabinofuranoside, DNA synthesis and methylation inhibitor
Drug Type	Small molecule
Formula	C₁₀H₁₂FN₅O₄
SMILES	C1=NC2=C(N=C(N=C2N1C3C(C(C(O3)CO)O)O)F)N
InChI	1S/C10H12FN5O4/c11-10-14-7(12)4-8(15-10)16(2-13-4)9-6(19)5(18)3(1-17)20-9/h2-3,5-6,9,17-19H,1H2,(H2,12,14,15)/t3-,5-,6+,9-/m1/s1
InChIKey	HBUBKKRHXORPQB-FJFJXFQQSA-N
CAS Number	21679-14-1
ChEMBL ID	CHEMBL1568
ChEBI ID	CHEBI:94701
TTD ID	D0F2XQ
Drug Bank ID	DB01073
KEGG ID	C21550
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Morin, Fludarabine
Partner Name	Morin
Disease Info	[ICD-11: 2A82]	Chronic lymphocytic leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	ACP1	hsa52
	Down-regulation	Expression	CXCL12	hsa6387
	Down-regulation	Expression	CXCR4	hsa7852
	Down-regulation	Expression	ITGB1	hsa3688
In Vitro Model	MEC-1	Chronic lymphocytic leukemia	Homo sapiens (Human)	CVCL_1870
Result	Morin treatment in CLL-derived Mec-1 cell line synergizes with conventional anticancer drugs currently used in CLL therapy by affecting leukemic cell viability and trafficking.